Mykletun Arnstein, Dahl Alv A, Haaland Carl Fredrik, Bremnes Roy, Dahl Olav, Klepp Olbjørn, Wist Erik, Fosså Sophie D
The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway.
J Clin Oncol. 2005 May 1;23(13):3061-8. doi: 10.1200/JCO.2005.08.048.
The prevalence of long-term survivors after treatment for testicular cancer (TC) is increasing, and most studies display normal or only slightly reduced quality of life (QOL) in TC survivors (TCSs). Impaired QOL is claimed to be associated with treatment modality and its side effects, although most studies in this field can be criticized for various methodologic shortcomings. We wanted to examine variation in long-term QOL in TCSs in relation to TC treatment modality, side effects, and TC-related stress in a large population.
QOL, side effects, and TC-related stress were self-rated by a questionnaire at a mean of 11 years of follow-up in 1,409 TCSs treated from 1980 to 1994. Norm data was obtained from 2,678 males who were representative of the general population. QOL was measured with the Short Form-36 (SF-36), and TC-related stress was measured with the Impact of Event Scale.
There were no clinically relevant differences in QOL between TCSs and age-adjusted norm data, although there was a slightly lowered SF-36 Physical Component Summary Score in TCSs. Variation of QOL in TCSs was related to self-reported side effects and TC-related stress but not to TC treatment modality. A significant association was found between side effects and TC-related stress.
TCSs do not suffer long term from reduced QOL, and only minor differences in QOL were found between different treatment modalities. TCSs who report more side effects or TC-related stress have increased risk for reduced QOL, but these associations are not explained by TC treatment modalities. Further QOL research in this area should explore vulnerability factors for side effects and TC-related stress.
睾丸癌(TC)治疗后长期存活者的比例正在上升,大多数研究表明TC幸存者(TCSs)的生活质量(QOL)正常或仅略有下降。尽管该领域的大多数研究因各种方法学缺陷而受到批评,但QOL受损被认为与治疗方式及其副作用有关。我们希望在大量人群中研究TCSs的长期QOL与TC治疗方式、副作用和TC相关应激之间的差异。
对1980年至1994年接受治疗的1409例TCSs进行平均11年的随访,通过问卷调查对QOL、副作用和TC相关应激进行自评。从2678名代表一般人群的男性中获取常模数据。使用简短健康调查问卷(SF-36)测量QOL,使用事件影响量表测量TC相关应激。
TCSs与年龄校正后的常模数据在QOL方面无临床相关差异,尽管TCSs的SF-36身体成分汇总得分略有降低。TCSs的QOL差异与自我报告的副作用和TC相关应激有关,而与TC治疗方式无关。副作用与TC相关应激之间存在显著关联。
TCSs不会长期受到QOL降低的影响,不同治疗方式之间在QOL方面仅发现微小差异。报告有更多副作用或TC相关应激的TCSs QOL降低的风险增加,但这些关联不能用TC治疗方式来解释。该领域进一步的QOL研究应探索副作用和TC相关应激的脆弱性因素。